Da an Genes: The stock has risen by more than 22% for two consecutive days, indicating multiple risks.

Da An Gene announced that the trading price of the company's stock has deviated by a cumulative increase of 22.05% for two consecutive trading days, indicating abnormal fluctuations. After conducting an investigation, the company stated that there have been no corrections or supplements to the previously disclosed information, the recent operations are normal, and no undisclosed significant information has been found in media reports. In November 2025, Guangzhou Pharmaceuticals Group intends to acquire equity to become an indirect controlling shareholder, and the matter is still in progress. The controlling shareholder and indirect controlling shareholder did not trade the company's stock during the abnormal fluctuation period. The company expects to disclose the 2025 annual report on April 3, 2026, and reminds investors to invest rationally.